论文部分内容阅读
美国著名咨询研究机构厄恩斯特-扬公司日前发表报告说,去年虽然初始股市场不振,但全球生物技术产业仍然从风险投资公司、私人和股市那里募集了100多亿美元资金,这是仅次于2000年的第二个好年头。这份全球生物技术产业报告说,充足的资金储备不但使生物技术产业有可能在市场动荡时期保持稳定,而且在与医药公司进行合作谈判时处于更有利地位。通过跨国合作、合并、兼
Ernst & Young, a well-known US consulting and research institute, recently released a report saying that although the initial stock market was sluggish last year, the global biotech industry still raised more than $ 10 billion from venture capital firms, private individuals and stock markets, Second in 2000, the second good year. The global biotech industry report said sufficient funding not only keeps the biotech industry stable during times of market turmoil, but is also in a better position to negotiate cooperative deals with pharmaceutical companies. Through cross-border cooperation, merger, both